AR017138A1 - Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos. - Google Patents
Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos.Info
- Publication number
- AR017138A1 AR017138A1 ARP980104740A ARP980104740A AR017138A1 AR 017138 A1 AR017138 A1 AR 017138A1 AR P980104740 A ARP980104740 A AR P980104740A AR P980104740 A ARP980104740 A AR P980104740A AR 017138 A1 AR017138 A1 AR 017138A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- alkoxy
- halo
- pharmaceutical
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001272 (C1-C4)-alkylene-phenyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010047139 Vasoconstriction Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 abstract 1
- -1 phenoxy, benzyloxy Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000025033 vasoconstriction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos antagonista del neuropéptido Y de la formula (I), en la cual Ar1 representa un fragmento estructural de la formula (II) o representa 1-o 2-naftilo, estando este ultimo grupo optativamente sustituido con uno o más sustituyentes seleccionados entre OH, halo o alcoxi C1-7; R1 representaC(O)NH2, alquilo C1-4 (optativamente sustituido o terminado con uno o más sustituyentes seleccionados entre hidroxi o amino)o, junto con R7 (en Ar1),formas de alquileno C2-3; R4 representa H, alquilo C1-7o alquilenfenilo C1-4 (estando el grupo fenilo de este ultimo grupo optativamente sustituido conuno o más sustituyentes seleccionados entre OH o alcoxi C1-4); R5 y R6 representan independientemente H, OH, alquilo C1-4, alcoxi C1-4 o halo; R7 representaH, OH, o, junto con R1, forma alquileno C2-3; R8 representa H, halo, OH, alcoxi C1-7, fenilo, fenoxi, benciloxi, -(CH2)nC(O)N(R10)R11, -(CH2)nN(H)C(O)N(R10)R11o -O(CH2)nC(O)OR10; R9 representa H, halo, OH o alcoxi C1-7; R2, R3, R10 y R11 representan independientemente H o alquilo C1-7; especialmente utilizablesen el tratamiento de enfermedades cardiovasculares, por ejemplo la vasoconstriccion. Se describen también formulaciones farmacéuticas que incluyen adichos compuestos, usos farmacéuticosde los mismos y procedimientos para su preparacion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9703414A SE9703414D0 (sv) | 1997-09-23 | 1997-09-23 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017138A1 true AR017138A1 (es) | 2001-08-22 |
Family
ID=20408331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980104740A AR017138A1 (es) | 1997-09-23 | 1998-09-22 | Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6127414A (es) |
| EP (1) | EP1017672B1 (es) |
| JP (1) | JP2001517651A (es) |
| KR (1) | KR20010024220A (es) |
| CN (1) | CN1279666A (es) |
| AR (1) | AR017138A1 (es) |
| AT (1) | ATE228500T1 (es) |
| AU (1) | AU9288998A (es) |
| BR (1) | BR9812492A (es) |
| CA (1) | CA2303528A1 (es) |
| DE (1) | DE69809782T2 (es) |
| EE (1) | EE200000171A (es) |
| IL (1) | IL134993A0 (es) |
| IS (1) | IS5410A (es) |
| NO (1) | NO20001483L (es) |
| PL (1) | PL339617A1 (es) |
| SE (1) | SE9703414D0 (es) |
| SK (1) | SK3602000A3 (es) |
| TR (1) | TR200000785T2 (es) |
| WO (1) | WO1999015498A1 (es) |
| ZA (1) | ZA988353B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9802075D0 (sv) * | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| US6312898B1 (en) * | 1999-04-15 | 2001-11-06 | Hormos Medical Oy, Ltd. | Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene |
| SE9902596D0 (sv) * | 1999-07-06 | 1999-07-06 | Astra Ab | Pharmaceutically active compounds |
| EP1095933A1 (en) | 1999-10-30 | 2001-05-02 | Aventis Pharma Deutschland GmbH | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| SE0101328D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Therapeutic treatment |
| JP4010951B2 (ja) * | 2001-05-15 | 2007-11-21 | 大正製薬株式会社 | アルギニン誘導体 |
| WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
| EP1680120A2 (en) | 2003-11-03 | 2006-07-19 | Probiodrug AG | Combinations useful for the treatment of neuronal disorders |
| FR2864830B1 (fr) * | 2004-01-06 | 2006-03-10 | Centre Nat Rech Scient | Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine |
| EP1713780B1 (en) | 2004-02-05 | 2012-01-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| KR100689499B1 (ko) * | 2005-10-26 | 2007-03-02 | 삼성전자주식회사 | 휴대단말기에서 키 설정 정보 디스플레이 방법 |
| WO2007064272A1 (en) * | 2005-11-29 | 2007-06-07 | Astrazeneca Ab | Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| EP2117540A1 (en) | 2007-03-01 | 2009-11-18 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| ES2481823T3 (es) | 2010-03-10 | 2014-07-31 | Probiodrug Ag | Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5) |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| KR20250120302A (ko) * | 2022-11-23 | 2025-08-08 | 라디오네틱스 온콜로지, 인코포레이티드 | 뉴로펩티드 y1 수용체(npy1r) 표적화 치료제 및 이의 용도 |
| WO2025144920A1 (en) * | 2023-12-28 | 2025-07-03 | Radionetics Oncology, Inc. | Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5873821A (en) * | 1992-05-18 | 1999-02-23 | Non-Invasive Technology, Inc. | Lateralization spectrophotometer |
| DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19544686A1 (de) * | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19544687A1 (de) * | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JP2000501107A (ja) * | 1996-01-09 | 2000-02-02 | イーライ・リリー・アンド・カンパニー | ベンズイミダゾリル神経ペプチドｙ受容体アンタゴニスト |
| CA2249222C (en) * | 1996-03-21 | 2005-11-08 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives |
| EP1007073A4 (en) * | 1996-06-04 | 2002-03-27 | Synaptic Pharma Corp | METHODS OF MODIFYING FOOD BEHAVIOR, COMPOUNDS USEFUL IN SAID METHODS, AND DNA ENCODING A HYPOTHALAMIC NEUROPEPTIDE Y / PEPTIDE YY Y5 RECEPTOR |
| CA2260982A1 (en) * | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
| ATE230403T1 (de) * | 1996-07-23 | 2003-01-15 | Neurogen Corp | Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande |
| PT918761E (pt) * | 1996-07-23 | 2003-09-30 | Neurogen Corp | Algumas amidas e aminas substituidas com derivados de benzilamina uma nova classe de ligandos especificos do neuropeptido y1 |
| DK0984778T3 (da) * | 1996-08-23 | 2002-09-16 | Agouron Pharma | Neuropeptid-Y-ligander |
| DE69720051T2 (de) * | 1996-12-03 | 2003-09-04 | Banyu Pharmaceutical Co., Ltd. | Harnstoffderivate |
| AU5410498A (en) * | 1996-12-12 | 1998-07-03 | Banyu Pharmaceutical Co., Ltd. | Pyrazole derivatives |
| WO1998025908A1 (en) * | 1996-12-13 | 1998-06-18 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyrazole derivatives |
| DE69729315T2 (de) * | 1996-12-16 | 2005-06-23 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazolderivate |
| WO1998033791A1 (en) * | 1997-02-04 | 1998-08-06 | Bristol-Myers Squibb Company | Dihydropyrimidone derivatives as npy antagonists |
| WO1998035944A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amides as npy5 receptor antagonists |
| JP2002241368A (ja) * | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物 |
| WO1998040356A1 (en) * | 1997-03-12 | 1998-09-17 | Banyu Pharmaceutical Co., Ltd. | Drugs containing aminopyridine derivatives as the active ingredient |
| US5889016A (en) * | 1997-06-26 | 1999-03-30 | Bristol-Myers Squibb Company | Dihydropyrimidone derivatives as NPY antagonists |
-
1997
- 1997-09-23 SE SE9703414A patent/SE9703414D0/xx unknown
-
1998
- 1998-09-11 ZA ZA988353A patent/ZA988353B/xx unknown
- 1998-09-21 CA CA002303528A patent/CA2303528A1/en not_active Abandoned
- 1998-09-21 EP EP98945708A patent/EP1017672B1/en not_active Expired - Lifetime
- 1998-09-21 AT AT98945708T patent/ATE228500T1/de not_active IP Right Cessation
- 1998-09-21 JP JP2000512808A patent/JP2001517651A/ja active Pending
- 1998-09-21 AU AU92889/98A patent/AU9288998A/en not_active Abandoned
- 1998-09-21 SK SK360-2000A patent/SK3602000A3/sk unknown
- 1998-09-21 IL IL13499398A patent/IL134993A0/xx unknown
- 1998-09-21 DE DE69809782T patent/DE69809782T2/de not_active Expired - Fee Related
- 1998-09-21 WO PCT/SE1998/001686 patent/WO1999015498A1/en not_active Ceased
- 1998-09-21 PL PL98339617A patent/PL339617A1/xx unknown
- 1998-09-21 CN CN98811336A patent/CN1279666A/zh active Pending
- 1998-09-21 US US09/171,779 patent/US6127414A/en not_active Expired - Fee Related
- 1998-09-21 TR TR2000/00785T patent/TR200000785T2/xx unknown
- 1998-09-21 KR KR1020007003029A patent/KR20010024220A/ko not_active Withdrawn
- 1998-09-21 BR BR9812492-7A patent/BR9812492A/pt not_active IP Right Cessation
- 1998-09-21 EE EEP200000171A patent/EE200000171A/xx unknown
- 1998-09-22 AR ARP980104740A patent/AR017138A1/es unknown
-
2000
- 2000-03-20 IS IS5410A patent/IS5410A/is unknown
- 2000-03-22 NO NO20001483A patent/NO20001483L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SE9703414D0 (sv) | 1997-09-23 |
| ZA988353B (en) | 1999-03-23 |
| BR9812492A (pt) | 2000-09-26 |
| TR200000785T2 (tr) | 2000-09-21 |
| IL134993A0 (en) | 2001-05-20 |
| NO20001483D0 (no) | 2000-03-22 |
| EE200000171A (et) | 2001-04-16 |
| CN1279666A (zh) | 2001-01-10 |
| DE69809782D1 (de) | 2003-01-09 |
| JP2001517651A (ja) | 2001-10-09 |
| EP1017672A1 (en) | 2000-07-12 |
| ATE228500T1 (de) | 2002-12-15 |
| AU9288998A (en) | 1999-04-12 |
| SK3602000A3 (en) | 2001-01-18 |
| WO1999015498A1 (en) | 1999-04-01 |
| DE69809782T2 (de) | 2003-07-17 |
| EP1017672B1 (en) | 2002-11-27 |
| US6127414A (en) | 2000-10-03 |
| PL339617A1 (en) | 2001-01-02 |
| CA2303528A1 (en) | 1999-04-01 |
| NO20001483L (no) | 2000-05-23 |
| IS5410A (is) | 2000-03-20 |
| KR20010024220A (ko) | 2001-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017138A1 (es) | Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos. | |
| AR033594A1 (es) | Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios | |
| MX9303263A (es) | Antagonistas de la angiotensina ii, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen | |
| DK0528858T3 (da) | Inhibitorer af dipeptidyl-aminopeptidase type IV | |
| ES2055523T3 (es) | Agentes antifungicos de triazol. | |
| ES2075121T3 (es) | Nuevos compuestos triciclicos. | |
| DK0705254T3 (da) | Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer | |
| ATE217629T1 (de) | Phosphonooxymethyl oder methylthiomethylether von taxanderivaten als antitumormittel | |
| UY24911A1 (es) | Compuestos de pirazina útiles en tratamiento de enfermedades y trastornos del snc | |
| DK0876366T3 (da) | Angiogenese-inhiberende pyridazinaminer | |
| ES2054825T3 (es) | Compuestos heterociclicos terapeuticos. | |
| AR024138A1 (es) | Inhibidores de la proliferacion celular | |
| ES2132351T3 (es) | Compuestos con un grupo sulfamoilo y amidino, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
| TR200401432T4 (tr) | Admantan türevleri | |
| ES2084831T3 (es) | Nuevo procedimiento para preparar formoterol y compuestos relacionados. | |
| PA8527401A1 (es) | 7-oxo-piridopirimidinas (ii) | |
| CO4990971A1 (es) | Agentes terapeuticos selectivos de la mmp-3, especialmente con una buena selecti vidad con respecto a las mmp-1,2,9y/o 14 | |
| MX9203845A (es) | Nuevos benzomorfanos, procedimieto para su preparacion y composiciones farmaceuticas que los contienen. | |
| DE69933885D1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
| AR044275A1 (es) | Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias | |
| AR041720A1 (es) | Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen | |
| DK0888379T3 (da) | Forbindelser tilhørende amidinium-familien, farmaceutiske præparater indeholdende disse forbindelser og anvendelsen deraf | |
| AR043271A1 (es) | Compuestos de dihidropironas con heterociclos unidos y su uso en composicines farmaceuticas que poseen actividad inhibidora de hiv proteasa | |
| DE69523581D1 (de) | Anti-helicobacter ester- oder carbamatderivate von azolonen |